Enhancing the QUAlity and Transparency Of health Research

EQUATOR resources in German | Portuguese | Spanish

New reporting guidelines in development

13/06/2012

The following guidelines are currently being developed:

CONSORT extension for reporting of health related quality of life (HRQoL) outcomes from trials
The development of this extension is discussed in a BMJ blog and a comment has been published in the Lancet: PMID 22078674

CONSORT extension for reporting randomised controlled trials of social interventions
For additional development information please visit:
http://www.spi.ox.ac.uk/research/centre-for-evidence-based-intervention/consort-study.html

CENT (CONSORT Extension for N-of-1 Trials)
An official extension of the CONSORT 2010 Statement is underway for reporting N-of-1 trials. This guidance provides a set of essential items to include when preparing reports of prospectively planned, multiple crossover single patient trials, which may or may not be randomized.  The CENT guidance is expected to become available in late 2012. Read a letter to the editor in JAMA on the importance of N-of-1 trials.

PRISMA-extension for equity relevant reviews
The development of this extension is discussed in a BMJ blog and in a PLoS blog. For additional development information please visit: http://equity.cochrane.org/equity-extension-prisma

The REporting of studies Conducted using Observational Routinely-collected Data (RECORD) statement
To develop reporting guidelines for observational studies using health data routinely collected for non-research purposes as an extension of the STROBE statement. A summary document has been prepared which includes a project overview, an outline of the main objectives and a call for stakeholders.

CIRCLe SMT project (Consensus on Interventions Reporting Criteria List Spinal Manipulative Therapy)
For additional development information please visit: http://www.circle-smt.com

STROBE-RDS (Reporting guidelines for Respondent Driven Sampling studies)
To develop guidelines for the reporting of Respondent Driven Sampling studies. Adapted from the STROBE guidelines for cross-sectional studies. The draft checklist is now available.

More information available here.

News archive

Email newsletter

Newsletter archive

Please complete the form below to sign up to receive our newsletters (view our privacy and data protection policy notice)

* indicates required

Latest guest blogger

  • Why did we develop TIDieR-Placebo?

    The TIDieR reporting guideline helps authors fully report their interventions, so that they can be used by others. However, TIDieR only explicitly covers active interventions, not placebo controls. The developers of the new TIDieR-Placebo extension explain why it is needed Read More